Literatur zu Kapitel 8.5: Immuntherapie der AML

 Druckversion

Autor/en: M. Stelljes, L. Uharek
Letzte Änderung: 01.07.2008

• Appelbaum FR.
  Antibody-targeted therapy for myeloid leukemia.
  Sem Hematol 1999;36(Suppl6):2-8.




• Blaise D et al.
  The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
  Leuk Lymphoma 1997;25(5-6):469-478.




• Galea-Lauri J.
  Immunological weapons against acute myeloid leukaemia.
  Immunology 2002;107(1):20-27.




• Goulmy E.
  Minor histocompatibility antigens: from transplantation problems to therapy of cancer.
  Hum Immunol 2006;67(6):433-438.




• Greiner J, Dohner H, Schmitt M.
  Cancer vaccines for patients with acute myeloid leukemia - defintion of leukemia-associated antigens and current clinical protocols targeting these antigens.
  Haematologica 2006;91(12):1653-1661.




• Kolb HJ et al.
  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
  Blood 1990;76(12):2462-2465.




• Kolb HJ et al.
  Graft-versus-leukemia reactions in allogeneic chimeras.
  Blood 2004;103(3):767-776.




• Larson RA et al.
  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
  Cancer 2005;104(7):1442-1452.




• Mailander V et al.
  Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.
  Leukemia 2004;18(1):165-166.




• Meloni G et al.
  Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.
  Blood 1994;84(7):2158-2163.




• Miller JS et al.
  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
  Blood 2005;105(8):3051-3057.




• Qazilbash MH et al.
  PR1 vaccine after hematopoietic stem cell transplantation.
  Biol Blood Marrow Transplant 2006;12(2):16.




• Rusakiewicz S, Molldrem JJ.
  Immunotherapeutic peptide vaccination with leukemia-associated antigens.
  Curr Opin Immunol 2006;18(5):599-604.




• Schmid C et al.
  Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
  Leukemia 2004;18(8):1430-1433.




• Taksin AL et al.
  High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group.
  Leukemia 2007;21(1):66-71.




• Gleissner B et al.
  Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials.
  Onkologie 2007;30(12):657-62.




• Thomas X et al.
  Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
  Leukemia 2007;21(3):453-461.




• van Bergen CA et al.
  Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
  Blood 2007;109(9):4089-4096.

Herausgeber: Prof. Dr. H. Link
Herausgeberbeirat: Prof. Dr. P. Albers, Prof. Dr. R. Andreesen, Priv.-Doz. Dr. A. Böhme, Prof. Dr. C. Bokemeyer, Prof. Dr. U. Creutzig, Prof. Dr. G. Ehninger, Prof. Dr. M. Freund, Prof. Dr. C. Garbe, Dr. N. Gökbuget, Prof. Dr. M. Hallek, Prof. Dr. J.T. Hartmann, Prof. Dr. R. Hehlmann, Prof. emerit. Dr. H. Heimpel, Prof. Dr. A. Hochhaus, Prof. Dr. K. Höffken, Dr. G. Hübner, Prof. Dr. Th. Junginger, Priv.-Doz. Dr. U. Kaiser, Priv.-Doz. Dr. R. Kath, Prof. Dr. C.-H. Köhne, Dr. R. Mahlberg, Prof. Dr. A. Matzdorff, Prof. Dr. R.-P. Müller, Prof. Dr. J. Preiß, Prof. Dr. H.-J. Schmoll, Prof. Dr. G. von Minckwitz